Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years
IntroductionThe adverse effects of neuromuscular junction dysfunctions caused by immune checkpoint inhibitor (ICI) drugs have not been thoroughly assessed in the clinics.ObjectiveTo assess the neuromuscular junction dysfunctions in cancer patients with adverse events caused by ICI therapy by searchi...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.778635/full |
| _version_ | 1798039492544692224 |
|---|---|
| author | Ping Zhang Donghui Lao Haoyan Chen Bin Zhao Qiong Du Qiong Du Qing Zhai Qing Zhai Xuan Ye Xuan Ye Bo Yu |
| author_facet | Ping Zhang Donghui Lao Haoyan Chen Bin Zhao Qiong Du Qiong Du Qing Zhai Qing Zhai Xuan Ye Xuan Ye Bo Yu |
| author_sort | Ping Zhang |
| collection | DOAJ |
| description | IntroductionThe adverse effects of neuromuscular junction dysfunctions caused by immune checkpoint inhibitor (ICI) drugs have not been thoroughly assessed in the clinics.ObjectiveTo assess the neuromuscular junction dysfunctions in cancer patients with adverse events caused by ICI therapy by searching the Food and Drug Administration Adverse Event Reporting System (FAERS) database.MethodsThe FAERS data from January 2004 to December 2020 were collected to analyze the association between neuromuscular connection dysfunction and ICI use. Disproportionate analysis and Bayesian analysis were used to quantify the association between the neuromuscular junction dysfunctions and ICIs. The onset time and outcome of neuromuscular junction dysfunctions in different ICI regimens were also compared.ResultsOut of 88,617 adverse event reports, 557 neuromuscular junction dysfunction reports (0.63%) were analyzed. Marketed ICI drugs, including ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, cemiplimab, avelumab, as well as their combinations, showed positive associations with four detection methods. Most of the adverse event reports were associated with the use of nivolumab (53.32%) and pembrolizumab (31.96%). However, nivolumab-related neuromuscular junction dysfunctions were similar with pembrolizumab (33.33% vs 33.14%, p > 0.05). The onset time of neuromuscular junction dysfunctions showed no significant difference among different ICIs (p > 0.05).ConclusionsAnalysis of FAERS data identified that over 30% (32.85%) of reports of neuromuscular junction dysfunctions resulted in death. Ongoing monitoring, risk evaluations, and further comparative studies of ICIs should be considered. |
| first_indexed | 2024-04-11T21:54:38Z |
| format | Article |
| id | doaj.art-156d8e469e7d48f19dd3eb35ff4b51b3 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T21:54:38Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-156d8e469e7d48f19dd3eb35ff4b51b32022-12-22T04:01:09ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-08-011310.3389/fimmu.2022.778635778635Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 yearsPing Zhang0Donghui Lao1Haoyan Chen2Bin Zhao3Qiong Du4Qiong Du5Qing Zhai6Qing Zhai7Xuan Ye8Xuan Ye9Bo Yu10Department of Pharmacy, Tongren Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, ChinaDepartment of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Pharmacy, Tongren Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, ChinaDepartment of Pharmacy Pharmacology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaSchool of Medicine, Fudan University, Shanghai, ChinaDepartment of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai, ChinaSchool of Medicine, Fudan University, Shanghai, ChinaDepartment of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai, ChinaSchool of Medicine, Fudan University, Shanghai, ChinaDepartment of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Pharmacy, Tongren Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, ChinaIntroductionThe adverse effects of neuromuscular junction dysfunctions caused by immune checkpoint inhibitor (ICI) drugs have not been thoroughly assessed in the clinics.ObjectiveTo assess the neuromuscular junction dysfunctions in cancer patients with adverse events caused by ICI therapy by searching the Food and Drug Administration Adverse Event Reporting System (FAERS) database.MethodsThe FAERS data from January 2004 to December 2020 were collected to analyze the association between neuromuscular connection dysfunction and ICI use. Disproportionate analysis and Bayesian analysis were used to quantify the association between the neuromuscular junction dysfunctions and ICIs. The onset time and outcome of neuromuscular junction dysfunctions in different ICI regimens were also compared.ResultsOut of 88,617 adverse event reports, 557 neuromuscular junction dysfunction reports (0.63%) were analyzed. Marketed ICI drugs, including ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, cemiplimab, avelumab, as well as their combinations, showed positive associations with four detection methods. Most of the adverse event reports were associated with the use of nivolumab (53.32%) and pembrolizumab (31.96%). However, nivolumab-related neuromuscular junction dysfunctions were similar with pembrolizumab (33.33% vs 33.14%, p > 0.05). The onset time of neuromuscular junction dysfunctions showed no significant difference among different ICIs (p > 0.05).ConclusionsAnalysis of FAERS data identified that over 30% (32.85%) of reports of neuromuscular junction dysfunctions resulted in death. Ongoing monitoring, risk evaluations, and further comparative studies of ICIs should be considered.https://www.frontiersin.org/articles/10.3389/fimmu.2022.778635/fullimmune checkpoint inhibitorneuromuscular junction dysfunctionadverse eventdata miningFAERS |
| spellingShingle | Ping Zhang Donghui Lao Haoyan Chen Bin Zhao Qiong Du Qiong Du Qing Zhai Qing Zhai Xuan Ye Xuan Ye Bo Yu Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years Frontiers in Immunology immune checkpoint inhibitor neuromuscular junction dysfunction adverse event data mining FAERS |
| title | Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years |
| title_full | Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years |
| title_fullStr | Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years |
| title_full_unstemmed | Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years |
| title_short | Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years |
| title_sort | neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy an analysis of faers data in the past 15 years |
| topic | immune checkpoint inhibitor neuromuscular junction dysfunction adverse event data mining FAERS |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.778635/full |
| work_keys_str_mv | AT pingzhang neuromuscularjunctiondysfunctionsduetoimmunecheckpointinhibitorstherapyananalysisoffaersdatainthepast15years AT donghuilao neuromuscularjunctiondysfunctionsduetoimmunecheckpointinhibitorstherapyananalysisoffaersdatainthepast15years AT haoyanchen neuromuscularjunctiondysfunctionsduetoimmunecheckpointinhibitorstherapyananalysisoffaersdatainthepast15years AT binzhao neuromuscularjunctiondysfunctionsduetoimmunecheckpointinhibitorstherapyananalysisoffaersdatainthepast15years AT qiongdu neuromuscularjunctiondysfunctionsduetoimmunecheckpointinhibitorstherapyananalysisoffaersdatainthepast15years AT qiongdu neuromuscularjunctiondysfunctionsduetoimmunecheckpointinhibitorstherapyananalysisoffaersdatainthepast15years AT qingzhai neuromuscularjunctiondysfunctionsduetoimmunecheckpointinhibitorstherapyananalysisoffaersdatainthepast15years AT qingzhai neuromuscularjunctiondysfunctionsduetoimmunecheckpointinhibitorstherapyananalysisoffaersdatainthepast15years AT xuanye neuromuscularjunctiondysfunctionsduetoimmunecheckpointinhibitorstherapyananalysisoffaersdatainthepast15years AT xuanye neuromuscularjunctiondysfunctionsduetoimmunecheckpointinhibitorstherapyananalysisoffaersdatainthepast15years AT boyu neuromuscularjunctiondysfunctionsduetoimmunecheckpointinhibitorstherapyananalysisoffaersdatainthepast15years |